Locally advanced cervical cancer
Conditions
Interventions
Observation group:None
Sponsors
Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: Cervical cancer patients planned for interstitial brachytherapy, including: 1. Pathological diagnosis: Histologically confirmed cervical squamous cell carcinoma, adenocarcinoma, or other types, with clear HPV status (determined by p16 immunohistochemical testing). 2.Clinical stage: FIGO 2018 stage IIIa-IVa. 3.Treatment type: Receiving radical concurrent chemoradiotherapy; or not receiving neoadjuvant chemotherapy, or having suboptimal tumor regression after neoadjuvant chemotherapy (tumor diameter >=5 cm). 4.General condition: Age 18-85 years; performance status ECOG score 70; normal blood count and liver/kidney function (e.g., hemoglobin >=90 g/L, neutrophils >=1.5×10?/L, serum creatinine <=1.5×ULN, ALT/AST <=2.5×ULN).
Exclusion criteria
Exclusion criteria: 1. Previous history of brachytherapy. 2. Concurrent other malignant tumors or serious underlying diseases (such as active infections of the urinary or gastrointestinal systems, uncontrolled cardiac conditions, coagulation disorders, uremia, or uncontrolled infectious diseases). 3. Pregnant or lactating women. 4. Patients unable to tolerate MRI examinations (e.g., due to intrauterine devices, claustrophobia) may be excluded on a case-by-case basis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Two-year local control rate; | — |
Countries
China
Contacts
Public ContactChen Haiyan, Yang Cuiping
Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital
Outcome results
None listed